NO20015845L - Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister - Google Patents

Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister

Info

Publication number
NO20015845L
NO20015845L NO20015845A NO20015845A NO20015845L NO 20015845 L NO20015845 L NO 20015845L NO 20015845 A NO20015845 A NO 20015845A NO 20015845 A NO20015845 A NO 20015845A NO 20015845 L NO20015845 L NO 20015845L
Authority
NO
Norway
Prior art keywords
benzhydryl
azabicyclo
methoxybenzyl
oct
isopropyl
Prior art date
Application number
NO20015845A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015845D0 (no
Inventor
Stephen Sargent Massett
George Joseph Quallich
Peter Robert Rose
Lewin Theophilus Wint
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20015845D0 publication Critical patent/NO20015845D0/no
Publication of NO20015845L publication Critical patent/NO20015845L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20015845A 1999-06-01 2001-11-30 Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister NO20015845L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13699599P 1999-06-01 1999-06-01
PCT/IB2000/000663 WO2000073303A1 (en) 1999-06-01 2000-05-17 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-amine citrate as nk-1 receptor antagonists

Publications (2)

Publication Number Publication Date
NO20015845D0 NO20015845D0 (no) 2001-11-30
NO20015845L true NO20015845L (no) 2002-01-30

Family

ID=22475353

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015845A NO20015845L (no) 1999-06-01 2001-11-30 Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyklo(2.2.2)okt-3-yl)-(5-isopropyl-2-metoksybenzyl)-amin-citrat som NK-1-reseptorantagonister

Country Status (38)

Country Link
US (1) US6387925B1 (zh)
EP (1) EP1181289A1 (zh)
JP (1) JP2003501353A (zh)
KR (1) KR20020005055A (zh)
CN (1) CN1353712A (zh)
AP (1) AP2001002350A0 (zh)
AR (1) AR029753A1 (zh)
AU (1) AU767331B2 (zh)
BG (1) BG106139A (zh)
BR (1) BR0011125A (zh)
CA (1) CA2372236A1 (zh)
CO (1) CO5170468A1 (zh)
CR (1) CR6513A (zh)
CZ (1) CZ20014270A3 (zh)
DZ (1) DZ3051A1 (zh)
EA (1) EA004206B1 (zh)
EE (1) EE200100655A (zh)
GT (1) GT200000086A (zh)
HK (1) HK1046407A1 (zh)
HN (1) HN2000000076A (zh)
HR (1) HRP20010884A2 (zh)
HU (1) HUP0201798A3 (zh)
IL (1) IL145952A0 (zh)
IS (1) IS6129A (zh)
MX (1) MXPA01012328A (zh)
NO (1) NO20015845L (zh)
NZ (1) NZ514762A (zh)
OA (1) OA11955A (zh)
PA (1) PA8496001A1 (zh)
PE (1) PE20010155A1 (zh)
PL (1) PL352715A1 (zh)
SK (1) SK17342001A3 (zh)
SV (1) SV2002000092A (zh)
TN (1) TNSN00119A1 (zh)
TR (1) TR200103472T2 (zh)
UY (1) UY26177A1 (zh)
WO (1) WO2000073303A1 (zh)
ZA (1) ZA200109839B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503859A (ja) * 2002-10-04 2006-02-02 メルク シャープ エンド ドーム リミテッド 受容体拮抗薬としてのアザ二環式スピロエーテル誘導体
PT1638937E (pt) * 2003-06-18 2009-01-27 Teva Pharma Forma xiv cristalina de fluvastatina sódica, processos para a sua preparação, composições que a contêm e métodos de utilização
US7371906B2 (en) 2004-08-24 2008-05-13 Eastman Kodak Company Process for photo-oxidative stability improvements
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN110577522B (zh) * 2018-06-07 2022-12-27 东莞市东阳光动物保健药品有限公司 马罗匹坦柠檬酸盐新晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
RU2103269C1 (ru) * 1991-05-31 1998-01-27 Пфайзер Инк. Производные хинуклидина или их фармацевтически приемлемые соли и фармацевтическая композиция
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions

Also Published As

Publication number Publication date
NZ514762A (en) 2002-12-20
CN1353712A (zh) 2002-06-12
AU767331B2 (en) 2003-11-06
CR6513A (es) 2003-11-25
TR200103472T2 (tr) 2002-05-21
CA2372236A1 (en) 2000-12-07
CO5170468A1 (es) 2002-06-27
IS6129A (is) 2001-10-26
JP2003501353A (ja) 2003-01-14
EA004206B1 (ru) 2004-02-26
PE20010155A1 (es) 2001-02-08
SV2002000092A (es) 2002-02-05
KR20020005055A (ko) 2002-01-16
HUP0201798A3 (en) 2002-10-28
AR029753A1 (es) 2003-07-16
IL145952A0 (en) 2002-07-25
DZ3051A1 (fr) 2004-03-27
TNSN00119A1 (fr) 2005-11-10
SK17342001A3 (sk) 2002-10-08
BR0011125A (pt) 2002-02-19
MXPA01012328A (es) 2002-07-30
PA8496001A1 (es) 2002-07-30
AP2001002350A0 (en) 2001-12-31
OA11955A (en) 2006-04-13
WO2000073303A1 (en) 2000-12-07
US6387925B1 (en) 2002-05-14
EA200100982A1 (ru) 2002-06-27
EE200100655A (et) 2003-02-17
HUP0201798A2 (en) 2002-09-28
BG106139A (bg) 2002-05-31
AU4424600A (en) 2000-12-18
PL352715A1 (en) 2003-09-08
EP1181289A1 (en) 2002-02-27
HK1046407A1 (zh) 2003-01-10
HRP20010884A2 (en) 2003-04-30
HN2000000076A (es) 2001-02-02
GT200000086A (es) 2001-11-21
ZA200109839B (en) 2003-01-29
UY26177A1 (es) 2000-12-29
CZ20014270A3 (cs) 2002-08-14
NO20015845D0 (no) 2001-11-30

Similar Documents

Publication Publication Date Title
NO20021450L (no) Cykliske aminforbindelser som CCR5-antagonister
NO20004606D0 (no) FremgangsmÕte for fremstilling av epoksider fra olefiner
DK1173440T3 (da) Tetracycliske azepinoindolforbindelser som 5-HT receptorligander
HK1072052A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
IS5539A (is) 4-(2-ketó-1-bensímidazólinýl) píperidín efnasambönd sem mótlyf fyrir orl 1-viðtaka
NO20025186D0 (no) FremgangsmÕte for syntese av en ecteinascidinforbindelse
NO20004261L (no) 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister
NO20006039L (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
HK1041267A1 (zh) 作為緩激肽拮抗劑的雜環苯磺酰胺化合物
NO20016187L (no) Polymorfer av krystallinske (2-benzhydryl-1- azabicyclo(2,2,2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-ammoniumklorid som NK-1 reseptor antagonister
NO20014356L (no) Bifenylderivater som antagonister av neurokinin-1 reseptoren
NO20015845D0 (no) Polymorfe forbindelser av krystallinske (2-benzhydryl-1- azabicyclo(2.2.2)oct-3-yl)-(5-iso-propyl-2-metoksybenzyl)-amincitrat som NK-1 reseptor antagonister
NO985970L (no) Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO20000965D0 (no) Fremgangsmåte for fremstilling av veksthormon-utskillende forbindelser
NO20010629D0 (no) Fremgangsmåte for fremstilling av en ikke-krystallinsk anhydratform av paroksetinhydroklorid
DK1133495T3 (da) Semihydrochlorid af 8-cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyre
NO20014001D0 (no) Fremgangsmate for screening av en forbindelse som har affinitet for vitamin D reseptor
DK1207159T3 (da) Heteroaromatiske derivater som dopamin-D4-receptorantagonister
AU2002334100A1 (en) Azabicyclic amine derivatives as nk-1 receptor antagonists
DK1200402T3 (da) Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
ID25461A (id) Turunan 2-ariletil-(piperidin-4-ilmetil)amina sebagai antagonis reseptor muskarinik
IT1312000B1 (it) Procedimento per la preparazione di composti semiconduttori.
FR2800064B1 (fr) Procede de preparation d'un compose de type benzofurane ou benzothiophene

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application